

1 Validity of the Somatic Complaints Scales of the MMPI-2-RF in an Outpatient Chronic Pain  
2 Clinic

3  
4 Lauren D. Mickens & Duyen M. Nghiem  
5 University of Houston-Clear Lake

6  
7 Dustin B. Wygant  
8 Eastern Kentucky University

9  
10 Robert L. Umlauf  
11 VA Tennessee Valley Healthcare System

12  
13 Ryan J. Marek  
14 Sam Houston State University  
15

16 Author Notes:

17 This is a post-review version and may differ slightly from the final published version. Please cite  
18 as follows:

19 Mickens, L.D., Nghiem, D.M., Wygant, D.B., Umlauf, R.L., & Marek, R.J. (2021).

20 Validity of the Somatic Complaints Scales of the MMPI-2-RF in an Outpatient  
21 Chronic Pain Clinic. *Journal of Clinical Psychology in Medical Settings*.  
22 <https://doi.org/10.1007/s10880-021-09766-4>

23  
24 Ryan J. Marek receives grant funding from the University of Minnesota Press unrelated  
25 to this project. Dustin B. Wygant is a paid consultant to the University of Minnesota Press,  
26 publisher of the MMPI-2-RF and Pearson Assessments.

27 Correspondence:

28 Please address all correspondence to: Ryan J. Marek, Ph.D., Sam Houston State University, 925  
29 City Central Avenue, Conroe, TX 77304. Email:rxm147@shsu.edu

## 30 Abstract

31 Chronic pain has become a significant medical issue. The Minnesota Multiphasic Personality  
32 Inventory-2-Restructured Form (MMPI-2-RF) is a broadband psychological test that has been  
33 validated for use across various medical settings and can aid in the assessment and treatment  
34 planning of chronic pain. In the current investigation, it was hypothesized that the somatic  
35 complaints scales of the MMPI-2-RF would demonstrate good convergent validity from a  
36 structured psychodiagnostic interview and other measures of pain and somatization, and lack  
37 gender bias. Patients (n = 200) who produced valid MMPI-2-RFs in an outpatient chronic pain  
38 clinic were included in the study. Patients were also administered the Modified Somatic  
39 Perception Questionnaire (MSPQ), Pain Disability Index (PDI), and the Structured Clinical  
40 Interview for DSM-IV-TR (SCID). Zero-order and partial correlations (controlling for gender)  
41 were calculated between MMPI-2-RF scale scores and other criteria. Stepdown hierarchical  
42 regression analyses were used to detect bias. By and large, higher scale scores on the  
43 somatic/cognitive scales of the MMPI-2-RF were modestly or substantially correlated with  
44 MSPQ scores, PDI scores, and SCID Somatization symptom count, even after controlling for  
45 gender. Regression analyses suggested that the MMPI-2-RF scale scores were not biased as a  
46 function of gender. These findings support the validity of specific MMPI-2-RF scales to help  
47 identify somatization and psychosocial functioning among patients with chronic pain.  
48 Identification of somatization early within the course of treatment of chronic pain may help focus  
49 treatment targets, including referrals for psychological interventions such as Cognitive Behavior  
50 Therapy for Chronic Pain.

51 Keywords: MMPI, Chronic Pain, Somatization, Assessment, PDI, MSPQ



74 the role psychosocial characteristics play in the presentation of chronic pain and the patients  
75 experience with adhering to treatment (McCord & Drerup, 2011).

76 Comorbid psychological disorders among patients with chronic pain include depression,  
77 anxiety, substance use, and somatization disorders (Marek, Anderson, et al., 2020; Von Korff et  
78 al., 2005). Somatization occurs when physical symptoms are indeed present (e.g., chronic pain,  
79 weakness) but result in the individual having excessive thoughts, feelings, and behaviors related  
80 to the physical symptoms (Association, 2013; Dimsdale et al., 2009). Notably, somatization  
81 tends to predict poorer treatment outcomes in chronic pain settings (Block et al., 2017; Marek,  
82 Block, et al., 2015; Marek et al., 2019). Although both men and women seek treatment for  
83 chronic pain, some studies suggest somatization tends to be reported more among women than  
84 men (Barsky et al., 2001; Bragazzi et al., 2014; Ladwig et al., 2001; Ladwig et al., 2000). Still,  
85 other studies suggest there are no gender differences or, if differences exist, they tend to be quite  
86 small (Delisle et al., 2012; Marek, Anderson, et al., 2020). On one hand, women may tend to  
87 score higher on measures of somatization because women tend to utilize health care services  
88 more than men (Ladwig et al., 2001). On the other hand, measures of somatization may include  
89 elements of bias that tend to exaggerate gender differences. Identifying methods of assessing  
90 somatization that is free of gender bias may be warranted.

91 The MMPI-2-RF (Ben-Porath & Tellegen, 2008/2011; Tellegen & Ben-Porath,  
92 2008/2011) is commonly used across medical settings (Marek & Ben-Porath, 2017) and the  
93 chronic pain comparison group data for men and women are also available. The authors of the  
94 MMPI-2-RF addressed numerous psychometric problems with its predecessors and the test  
95 yields better reliability and validity coefficients compared to its previous iterations. The MMPI-  
96 2-RF is comprised of 338 items, including nine validity scales, and 42 substantive scales. The

97 substantive scales of the test assess five domains congruent with contemporary models of  
98 psychopathology and is identified as one of the measures that align with the Hierarchical  
99 Taxonomy of Psychopathology (HiTOP) (Kotov et al., 2017).

100         Although the MMPI-2-RF measures several domains related to emotional and behavioral  
101 problems that can co-occur with chronic pain (e.g., mood, anxiety, substance abuse), the test also  
102 assesses somatization. An examination of the factor structure of the Specific Problems Scales of  
103 the MMPI-2-RF demonstrated four domains: Internalizing, Externalizing, Detachment, and  
104 Somatization (Marek, Anderson, et al., 2020; Sellbom, 2017). Across numerous medical samples  
105 (including chronic pain), the somatization factor tends to correlate most highly with external  
106 criteria related to somatization and demonstrates adequate discriminant validity against other  
107 criteria (including other internalizing criteria) (Marek, Anderson, et al., 2020). With regard to  
108 chronic pain treatment facilities, the scale scores of the MMPI-2-RF demonstrated good  
109 psychometric properties, including convergent and discriminant validity, and predicts outcomes  
110 after treatment (Tarescavage et al., 2015, 2018). The scale scores on the MMPI-2-RF also serve  
111 as a better differential diagnostic tools over the MMPI-2 (McCord & Drerup, 2011). Research  
112 has also elucidated that MMPI-2-RF scale scores are not be biased as a function of gender, race,  
113 or age among patients seeking bariatric surgery (Marek, Ben-Porath, et al., 2015). The MMPI-2-  
114 RF has also been developed to work well in the pre-surgical psychological evaluation of spine  
115 surgery and spinal cord stimulator (SCS) patients (Block & Ben-Porath, 2018). Indeed, the  
116 Somatic/Cognitive Specific Problems Scales tend to correlate well with criteria such as  
117 functional disability and pain and also predicts short-term outcomes in spine surgery/SCS  
118 settings (Block et al., 2013; Block et al., 2019; Block et al., 2017; Block et al., 2014; Marek,  
119 Ben-Porath, et al., 2020; Marek, Block, et al., 2015; Marek et al., 2019).

120 To date, the validity of the Somatic/Cognitive Specific Problems Scales of the MMPI-2-  
121 RF have been validated in a chronic pain sample (Tarescavage et al., 2015); however, validity of  
122 the MMPI-2-RF scale scores not been cross-validated in a secondary chronic pain treatment  
123 seeking sample and examinations of gender-bias have not been explored. Moreover, external  
124 criteria in previous studies (Marek, Anderson, et al., 2020; McCord & Drerup, 2011;  
125 Tarescavage et al., 2015) tend to focus more on broader psychosocial variables and are limited in  
126 scope regarding assessment of somatization. Additionally, limited research is available regarding  
127 the differential validity (predictive bias) of the MMPI-2-RF scale scores. Thus, the current  
128 investigation seeks to cross-validate the Somatic/Cognitive Specific Problems Scales of the  
129 MMPI-2-RF by using symptom counts of somatization-related disorders derived from a  
130 structured psychodiagnostic instrument and other self-report measures more narrowly focused to  
131 assess somatization. Additionally, MMPI-2-RF scale score bias will also be examined. It is  
132 hypothesized that the Somatic/Cognitive Specific Problems Scales of the MMPI-2-RF will yield  
133 good convergent validity in an outpatient chronic pain sample. Additionally, it is hypothesized  
134 that the Somatic/Cognitive Specific Problems Scales of the MMPI-2-RF will not exhibit gender  
135 bias in assessing somatization between men and women.

## 136 **Method**

### 137 **Participants**

138 A total of 230 patients who were seeking outpatient treatment for chronic low back pain  
139 were available. Of those, 30 patients were removed from further analyses because they produced  
140 an invalid MMPI-2-RF according to criteria outlined in the MMPI-2-RF Technical Manual  
141 (Tellegen & Ben-Porath, 2008/2011): Variable Response Inconsistency-Revised  $\geq 80$ , Fixed  
142 Response Inconsistency-Revised  $\geq 80$ , Infrequent Responses-Revised  $\geq 120$ , Infrequent

143 Psychopathology Responses  $\geq 100$ . Of the 200 patients included in analyses, 58.5% were women  
144 and 41.5% were men. A majority of the sample identified as being White (96.0%) whereas 3%  
145 identified as being Black, .5% identified as being Asian American, and .5% reported being of  
146 another ethnicity. The sample had a mean age of 50.12 years old (SD = 14.39) and reported an  
147 average of 12.83 years of education (SD = 2.07). Listed in Table 1 are additional demographic  
148 data associated with this sample. Use of this database was approved by the third author's  
149 Institutional Review Board and patients provided consent at the time of their evaluation that their  
150 archival data could be used for research.

### 151 **Measures**

152 *Minnesota Multiphasic Personality Inventory – 2 – Restructured Form (MMPI-2-RF;*  
153 *Ben-Porath & Tellegen, 2008/2011; Tellegen & Ben-Porath, 2008/2011).* The MMPI-2-RF is a  
154 338-item, self-report inventory that assesses personality and psychosocial functioning congruent  
155 with contemporary models of psychopathology/personality (Kotov et al., 2017; Sellbom, 2019).  
156 The MMPI-2-RF captures a broad range of psychological functioning, including internalizing,  
157 externalizing, thought disorder, interpersonal, and somatization. Notably, the scale scores of the  
158 MMPI-2-RF yield good reliability and validity (including convergent, discriminant, and  
159 predictive validity) coefficients when used with chronic low back pain patients (Marek,  
160 Anderson, et al., 2020; Tarescavage, 2015; Tarescavage et al., 2015).

161 *Pain Disability Index (PDI; Pollard, 1984).* The PDI is a 7-item, self-report measure that  
162 assesses how pain disrupts various domains of functioning (e.g., social activity, responsibilities).  
163 The scale score of the PDI yields good reliability and validity coefficients when used in various  
164 chronic pain settings (Jerome & Gross, 1991; Tait et al., 1990). In the current sample,  
165 Cronbach's alpha was equal to .88 (mean inter-item correlation = .51) indicating good reliability.

166            *Modified Somatic Perception Questionnaire (MSPQ; Main, 1983)*. The MSPQ is a 13-  
167 item, self-report measure that assesses somatic and autonomic perception in patients with chronic  
168 pain. Although the scale score of the measure yields some questionable psychometrics regarding  
169 its ability to predict functional disabilities and outcomes (Deyo et al., 1989; Donaldson et al.,  
170 2011). In the current sample, Cronbach's alpha was equal to .84 (mean inter-item correlation =  
171 .29) indicating good reliability.

172            *Structured Clinical Interview for DSM-IV-TR Disorders: Somatoform*  
173 *Disorders Module (SCID; First et al., 2002)*. The SCID used in this study is a structured clinical  
174 interview to aid in formulating reliable psychiatric diagnosis consistent with the DSM-IV-TR  
175 (Association, 2000). For the current study, only the somatoform disorders module was utilized.  
176 Standardized administration was modified to remove skip-out decision rules to fully assess the  
177 range of symptomatology for each of these conditions with a dimensional symptom  
178 count. Additionally, DSM-5 (Association, 2013) uses different criteria to diagnose somatic  
179 symptom-related disorders. Due to advances in understanding psychodiagnosis from a  
180 dimensional perspective (Kotov et al., 2017), examining the number of overall symptoms across  
181 somatization disorders likely serves as better dimensional proxy for severity of somatization-  
182 related functioning. Thus, a symptom count variable was used in the current study, such that  
183 more symptoms reported indicates more severe somatization.

#### 184 **Procedure**

185            Data were drawn from a retrospective, deidentified database. Patients consented to have  
186 their clinical data used archivally for research purposes. Participants were administered the  
187 MMPI-2-RF, MSPQ, PDI, and SCID somatoform disorders module as part of their routine  
188 clinical evaluations. Means and standard deviations were calculated by gender for each scale



189 score used in the study (Tables 2 and 3). Additionally, *t*-tests were calculated to test whether  
190 scale scores differed significantly and meaningfully between gender. Cohen's *d* effect sizes were  
191 calculated for each *t*-test. Pearson Product-Moment correlations (Table 4) were calculated to  
192 examine the convergent validity of the MMPI-2-RF Somatic/Cognitive Scales. Also contained in  
193 Table 4 are partial correlations controlling for gender.

194 To test whether the MMPI-2-RF Somatic/Cognitive scale scores are biased as a function  
195 of gender, stepdown hierarchical regression analyses were conducted (Lautenschlager &  
196 Mendoza, 1986). Briefly, a regression model that included only the MMPI-2-RF scale score as a  
197 predictor (prediction model) was compared with one that included that scale, the gender, and the  
198 interaction of the two (full model).  $R^2$  was examined to compare models (.010 = Small Effect  
199 Size; .090 = Medium Effect Size; .250 = Large Effect Size)(Cohen, 1988). If there is a  
200 significant increase in  $R^2$  between models, potential bias is occurring and follow-up tests to  
201 determine if bias is occurring in the slope or the intercept were then conducted. To conduct a test  
202 of slope bias, the full model is compared to a model with the MMPI-2-RF scale score and  
203 gender. If there is a significant increase in  $R^2$  between models, slope bias is present and intercept  
204 bias is then tested. To test for intercept bias when slope bias is present, the full model was  
205 compared to a model with the MMPI-2-RF scale score and the moderator. If there is a  
206 significant increase in  $R^2$  between models, intercept bias is present. If slope bias was not  
207 detected, intercept bias was then tested by comparing the prediction model with a model that  
208 includes the MMPI-2-RF scale score and gender. Again, a significant increase in  $R^2$  between  
209 models indicates that intercept bias is present. All continuous predictors were centered around  
210 their means and centered values were also used in the computation of the moderating variable.  
211 These results are reported in Table 5.

212

**Results**

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Listed in Table 2 are means, standard deviations, and inferential statistics between MMPI-2-RF Somatic/Cognitive scales and gender. By and large, women tended to score higher on a number of MMPI-2-RF Somatic/Cognitive scales, including Somatic Complaints, Head Pain Complaints, and Cognitive Complaints. These differences yielded small to medium effect sizes.

Displayed in Table 3 are means, standard deviations, and inferential statistics between the PDI scale score, MSPQ scale score, and SCID somatization symptom count broken down by gender. Women tended to score higher on the MSPQ compared to men and this difference yielded a medium effect size.

Listed in Table 4 are zero-order and partial correlations (controlling for gender) between the MMPI-2-RF Somatic/Cognitive scales and the criteria measures (PDI, MSPQ, and SCID somatization symptom count). The Somatic Complaints scale scores were positive and modestly associated with PDI scores and SCID somatization symptom count. A substantial association was founded between Somatic Complaint scale scores and MSPQ scales scores. Malaise scores were modestly related to PDI scores and MSPQ count and small to moderately related to SCID somatization symptom count. The Gastrointestinal Complaints scale score was small to modestly associated with SCID somatization symptom count and moderately associated with MSPQ scores. MSPQ scale scores were also modestly associated with Head Pain Complaints, Neurological Complaints, and Cognitive Complaints scale scores. Small to modest associates were evidenced between Head Pain Complaints, Neurological Complaints, and Cognitive Complaints scale scores and PDI scores and SCID somatization symptom count. When

234 comparing the zero-order correlations to the partial correlations, the magnitude of the  
235 associations did not substantially change as a result of controlling for gender.

236 Displayed in Table 5 are results of slope/intercept bias analyses of the MMPI-2-RF  
237 Somatic/Cognitive scales by gender with the three criteria (PDI, MSPQ, SCID somatization  
238 symptom count). No evidence of bias emerged when predicting PID scores and SCID  
239 somatization symptom count. When using the MSPQ as a dependent variable, analyses  
240 demonstrated significant increments in  $R^2$  when using Malaise, Neurological Complaints, and  
241 Cognitive Complaints scales. Although statistically significant, these increments were small in  
242 effect size. Nonetheless, slope and intercept bias analyses were conducted. None of the analyses  
243 supported indices of slope bias. Intercept bias was present in all three follow-up analyses, though  
244 the effect sizes were quite small. In all instances, Malaise, Neurological Complaints, and  
245 Cognitive Complaints scales tended to over-predict somatization in men and under-predict them  
246 in women.

## 247 **Discussion**

248 Overall, analyses largely supported the hypotheses. Notably, the Somatic/Cognitive  
249 Specific Problems Scales of the MMPI-2-RF tended to correlate well with two alternative self-  
250 report measures of somatic symptoms and converged well with clinician interview data from the  
251 SCID. Because women tended to score higher on several scales of the MMPI-2-RF, differential  
252 validity also needed to be considered. By and large, the MMPI-2-RF scale scores used in this  
253 study demonstrate little to no evidence of differentially predicting somatization across gender.

254 MMPI-2-RF scale scores converged well with external criteria. Notably, scale scores  
255 yielded good convergent validity coefficients with both self-report and interview-based methods  
256 of assessing for somatization. Past studies often relied on indices of functional disability, reports

257 of medical problems, and medical chart diagnoses that may infer a somatization component (e.g.,  
258 Chronic Fatigue Syndrome) (Block et al., 2013; Marek, Anderson, et al., 2020; Marek, Ben-  
259 Porath, et al., 2020; Tarescavage et al., 2015). The coefficients in the current investigation add to  
260 the current literature suggesting that the MMPI-2-RF Somatic/Cognitive scale scores yield good  
261 construct validity in chronic pain settings by using both interview and self-report data specific to  
262 the construct of somatization.

263 Descriptive information reported in this study demonstrated a common observation  
264 across medical samples. Notably, women tended to have higher scores on somatic scale scores  
265 across measures. However, consistent with some past reports (Delisle et al., 2012), these  
266 differences yielded small effect sizes. Once gender was controlled for, the MMPI-2-RF validity  
267 coefficients were not much affected. Follow-up analyses to test for potential gender bias in the  
268 MMPI-2-RF Somatic/Cognitive scale scores were largely unsupported. A few scale scores  
269 (Malaise, Neurological Complaints, and Cognitive Complaints) slightly over-predicted MSPQ  
270 scores for men and under-predicted MSPQ scores for women. However, these instances of  
271 intercept bias did not occur across other indices of somatization, including symptom count  
272 derived from a structured clinical interview. Because men tended to score lower on the MSPQ  
273 and women tended to score higher on the MSPQ, it is likely that the these observed effects  
274 reflect gender differences in the MSPQ vs. over-/under-prediction on the MMPI-2-RF scale  
275 scores. It is also important to note that the intercept bias coefficients in these analyses tended to  
276 be small in effect size. Thus, gender-based differential validity was not supported. Overall, there  
277 was a lack of differential validity in the MMPI-2-RF Somatic/Cognitive scale scores. Thus, the  
278 MMPI-2-RF Somatic/Cognitive scale scores are not biased as a function of gender among  
279 patients seeking treatment for chronic pain. Importantly, MMPI-2-RF scale scores tend to be

280 unbiased in their assessment of psychological constructs in medical settings as evidenced here  
281 and elsewhere (Marek, Ben-Porath, et al., 2015). Contemporary models of psychopathology  
282 (Kotov et al., 2017) suggest that somatization is a separate spectrum from internalizing (mood,  
283 anxiety, distress) and empirical evidence to date supports this claim (Kotov et al., 2011; Marek,  
284 Anderson, et al., 2020; Sellbom, 2017). Using a test, such as the MMPI-2-RF, can offer a more  
285 delineated assessment of somatization while also providing assessment of distress, mood,  
286 anxiety, and substance-related problems. To add MMPI-2-RF is one of the recommended  
287 measures listed to assess HiTOP (Kotov et al., 2017). Additionally, using a test such as the  
288 MMPI-2-RF limits the need to administer multiple screeners in piecemeal fashion, some of  
289 which have not been well-validated in medical populations.

290         These findings also point towards broader implications in future research regarding  
291 somatization. Similar to past studies (Barsky et al., 2001; Bragazzi et al., 2014; Ladwig et al.,  
292 2001; Ladwig et al., 2000), women in the current investigation reported greater severity of  
293 somatization than men; however, scale differences did not result in differential validity  
294 suggesting that the MMPI-2-RF accurately assesses somatization regardless of gender. Ladwig et  
295 al. (2001) reported that women were at a much higher risk for somatization than men, but gender  
296 differences in risk for somatization were similar once emotional distress and socioeconomic  
297 status were accounted for. Ladwig et al. (2001)'s study implied that other sociodemographic and  
298 psychological variables may play a role in somatic symptom expression. Bragazzi et al. (2014)  
299 also reported that cultural differences accounted for disparities in scores on the MSPQ,  
300 suggesting that somatic symptom expression may be influenced by cultural norms. Overall,  
301 future research needs to better understand and account for cultural differences or socioeconomic

302 status in assessing somatization and understanding how those demographics affect treatment  
303 outcomes.

304         The current investigation has several limitations. Because the sample reported that they  
305 were predominately white/Caucasian, differential validity of the MMPI-2-RF Somatic/Cognitive  
306 scale scores as a function of race/ethnicity was not able to be conducted due to low statistical  
307 power. Nonetheless, other studies using chronic pain patients and bariatric surgery patients  
308 suggest that the MMPI-2-RF scales are likely not biased as a function of race/ethnicity (Marek,  
309 Anderson, et al., 2020; Marek, Ben-Porath, et al., 2015). Another limitation was the lack of  
310 treatment outcome data. Although the MMPI-2-RF Somatic/Cognitive scale scores tend to  
311 predict emotional functioning and functional disability after treatment in both non-surgical  
312 (Tarescavage et al., 2018) and surgical (Block et al., 2017; Marek, Block, et al., 2015) settings,  
313 no study to date has examined how somatization changes as a function of treatment. Follow-up  
314 studies examining predictors of treatment outcomes should consider using a measure of  
315 somatization in addition to measures of internalizing and externalizing functioning.

316         An important implication of the current investigation is how these results will likely carry  
317 over to the MMPI-3 (Ben-Porath & Tellegen, 2020a, 2020b) and to the broader understanding of  
318 psychosocial functioning. Many of the Somatic/Cognitive Scales of the MMPI-2-RF are being  
319 carried over and enhanced for the MMPI-3. New normative data have been collected and item  
320 content has been revised and updated. The MMPI-3 is aligned with contemporary models of  
321 psychopathology, and comparison group data for spine surgery patients will be available when  
322 the new test is published. Somatic Complaints, Malaise, Neurological Complaints, and Cognitive  
323 Complaints will all appear on the MMPI-3 (with some enhancements), along with a newly  
324 developed scales addressing eating-related concerns, impulsivity, self-importance, and

325 compulsivity. Because the test will be similar to the MMPI-2-RF, results from the current  
326 investigation will likely provide some continuity for the MMPI-3. Across both the MMPI-2-RF  
327 and MMPI-3, these tests differentially assess problems with mood, anxiety, distress, and  
328 somatization. Because many patients who present in medical settings often exhibit a fair amount  
329 of demoralization (Fava et al., 1995), tests' and measures' discriminant validity are often  
330 confounded. By using psychological tests and measures that appropriately differentiate between  
331 these constructs, practitioners can better understand their patients and can use test scores to aid in  
332 differential diagnosis and treatment planning. Taken together, the MMPI-2-RF is a well-  
333 validated, broadband test of personality and psychosocial functioning. The test can assess for a  
334 wide-range of functioning, including somatization. Accumulating evidence also suggests that the  
335 scale scores of the test tend to not be biased as a function of demographics. When used in a  
336 chronic pain setting, mental health professionals can gather a vast amount of information about  
337 the client that are pertinent to the diagnosis and treatment planning of their patients in under an  
338 hour.

339 **Compliance with Ethical Standards**

340 Funding: None.

341 Conflict of Interest: The first author receives grant funding from the University of  
342 Minnesota Press unrelated to this project. The third author is a paid consultant to the University  
343 of Minnesota Press, publisher of the MMPI-2-RF and Pearson Assessments. The other authors  
344 report no conflicts of interest.

345 Ethical approval: All procedures performed in studies involving human participants were  
346 in accordance with the ethical standards of the institutional and/or national research committee  
347 and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.  
348 This article does not contain any studies with animals performed by any of the authors.

349 Informed consent: Informed consent was obtained from all individual participants  
350 included in the study at the time the data were collected.

351

352



## 353 References

354 Association, A. P. (2000). *Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR*.

355 American Psychiatric Association.

356

357 Association, A. P. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.).

358 American Psychiatric Publishing.

359 <https://doi.org/10.1176/appi.books.9780890425596.734227>

360

361 Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003, Nov 10). Depression and pain

362 comorbidity: a literature review. *Arch Intern Med*, *163*(20), 2433-2445.

363 <https://doi.org/10.1001/archinte.163.20.2433>

364

365 Barsky, A. J., Peekna, H. M., & Borus, J. F. (2001, Apr). Somatic symptom reporting in women

366 and men. *J Gen Intern Med*, *16*(4), 266-275.

367 <https://www.ncbi.nlm.nih.gov/pubmed/11318929>

368 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1495200/pdf/jgi\\_00229.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1495200/pdf/jgi_00229.pdf)

369

370 Ben-Porath, Y. S., & Tellegen, A. (2008/2011). *The Minnesota Multiphasic Personality*

371 *Inventory-2 Restructured Form (MMPI-2-RF): Manual for administration, scoring, and*

372 *interpretation*. University of Minnesota Press.

373 [http://www.pearsonassessments.com/HAIWEB/Cultures/en-](http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?Pid=PAg523&Mode=summary)

374 [us/Productdetail.htm?Pid=PAg523&Mode=summary](http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?Pid=PAg523&Mode=summary)

375

- 376 Ben-Porath, Y. S., & Tellegen, A. (2020a). *The Minnesota Multiphasic Personality Inventory-3:*  
377 *Manual for administration, scoring, and interpretation.* University of Minnesota Press.  
378
- 379 Ben-Porath, Y. S., & Tellegen, A. (2020b). *The Minnesota Multiphasic Personality Inventory-3:*  
380 *Technical Manual.* University of Minnesota Press.  
381
- 382 Block, A. R., & Ben-Porath, Y. S. (2018). *MMPI-2-RF User's Guide for the Spine Surgery and*  
383 *Spinal Cord Stimulator Candidate Interpretive Reports.* University of Minnesota Press.  
384
- 385 Block, A. R., Ben-Porath, Y. S., & Marek, R. J. (2013, Sep 21). Psychological risk factors for  
386 poor outcome of spine surgery and spinal cord stimulator implant: a review of the  
387 literature and their assessment with the MMPI-2-RF. *Clin Neuropsychol*, 27(1), 81-107.  
388 <https://doi.org/10.1080/13854046.2012.721007>  
389
- 390 Block, A. R., Marek, R. J., & Ben-Porath, Y. S. (2019, Jun). Patient Activation Mediates the  
391 Association Between Psychosocial Risk Factors and Spine Surgery Results. *J Clin*  
392 *Psychol Med Settings*, 26(2), 123-130. <https://doi.org/10.1007/s10880-018-9571-x>  
393
- 394 Block, A. R., Marek, R. J., Ben-Porath, Y. S., & Kukal, D. (2017, Jan). Associations Between  
395 Pre-Implant Psychosocial Factors and Spinal Cord Stimulation Outcome: Evaluation  
396 Using the MMPI-2-RF. *Assessment*, 24(1), 60-70.  
397 <https://doi.org/10.1177/1073191115601518>  
398

- 399 Block, A. R., Marek, R. J., Ben-Porath, Y. S., & Ohnmeiss, D. D. (2014). Associations Between  
400 Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) Scores,  
401 Workers' Compensation Status, and Spine Surgery Outcome. *Journal of Applied*  
402 *Biobehavioral Research, 19*(4), 248-267.
- 403
- 404 Bragazzi, N. L., Puente, G. D., & Natta, W. M. (2014). Somatic perception, cultural differences  
405 and immigration: results from administration of the Modified Somatic Perception  
406 Questionnaire (MSPQ) to a sample of immigrants. *Psychol Res Behav Manag, 7*, 161-  
407 166. <https://doi.org/10.2147/PRBM.S55393>
- 408
- 409 Cohen, J. (1988). *Statistical power analysis for the behavioral sciences* (2nd ed.). Psychology  
410 Press.
- 411
- 412 Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M.,  
413 Porter, L., & Helmick, C. (2018, Sep 14). Prevalence of Chronic Pain and High-Impact  
414 Chronic Pain Among Adults - United States, 2016. *Mmwr-Morbidity and Mortality*  
415 *Weekly Report, 67*(36), 1001-1006. <https://doi.org/DOI 10.15585/mmwr.mm6736a2>
- 416
- 417 Delisle, V. C., Beck, A. T., Dobson, K. S., Dozois, D. J., & Thombs, B. D. (2012). Revisiting  
418 gender differences in somatic symptoms of depression: much ado about nothing? *PLoS*  
419 *one, 7*(2).
- 420

- 421 Dersh, J., Polatin, P. B., & Gatchel, R. J. (2002, Sep-Oct). Chronic pain and psychopathology:  
422 research findings and theoretical considerations. *Psychosomatic Medicine*, *64*(5), 773-  
423 786. <https://doi.org/10.1097/01.psy.0000024232.11538.54>  
424
- 425 Deyo, R. A., Walsh, N. E., Schoenfeld, L. S., & Ramamurthy, S. (1989, May). Studies of the  
426 Modified Somatic Perceptions Questionnaire (MSPQ) in patients with back pain.  
427 Psychometric and predictive properties. *Spine (Phila Pa 1976)*, *14*(5), 507-510.  
428 <https://doi.org/10.1097/00007632-198905000-00006>  
429
- 430 Dimsdale, J., Creed, F., & Disorders, D.-V. W. o. S. S. (2009, Jun). The proposed diagnosis of  
431 somatic symptom disorders in DSM-V to replace somatoform disorders in DSM-IV--a  
432 preliminary report. *J Psychosom Res*, *66*(6), 473-476.  
433 <https://doi.org/10.1016/j.jpsychores.2009.03.005>  
434
- 435 Donaldson, M. B., Learman, K., Wright, A., Brown, C., Howes, C., & Cook, C. E. (2011, Jan).  
436 Factor structure and concurrent/convergent validity of the modified somatic perception  
437 questionnaire and pain beliefs instrument. *J Manipulative Physiol Ther*, *34*(1), 30-36.  
438 <https://doi.org/10.1016/j.jmpt.2010.11.002>  
439
- 440 Dueñas, M., Ojeda, B., Salazar, A., Mico, J. A., & Failde, I. (2016). A review of chronic pain  
441 impact on patients, their social environment and the health care system. *Journal of pain*  
442 *research*, *9*, 457.  
443 [https://www.dovepress.com/front\\_end/cr\\_data/cache/pdf/download\\_1598116760\\_5f4153](https://www.dovepress.com/front_end/cr_data/cache/pdf/download_1598116760_5f4153)

- 444 98ba431/JPR-105892-a-review-of-chronic-pain-impact-on-patients--their-social-  
445 en\_062816.pdf  
446
- 447 Ehde, D. M., Dillworth, T. M., & Turner, J. A. (2014, Feb-Mar). Cognitive-Behavioral Therapy  
448 for Individuals With Chronic Pain Efficacy, Innovations, and Directions for Research.  
449 *American Psychologist*, 69(2), 153-166. <https://doi.org/10.1037/a0035747>  
450
- 451 Fava, G. A., Freyberger, H. J., Bech, P., Christodoulou, G., Sensky, T., Theorell, T., & Wise, T.  
452 N. (1995). Diagnostic-Criteria for Use in Psychosomatic Research. *Psychotherapy and*  
453 *psychosomatics*, 63(1), 1-8. <https://doi.org/Doi.10.1159/000288931>  
454
- 455 First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. (2002). *Structured clinical interview*  
456 *for DSM-IV-TR axis I disorders, research version, patient edition*.  
457
- 458 Jerome, A., & Gross, R. T. (1991, Oct). Pain disability index: construct and discriminant  
459 validity. *Arch Phys Med Rehabil*, 72(11), 920-922. [https://doi.org/10.1016/0003-](https://doi.org/10.1016/0003-9993(91)90012-8)  
460 [9993\(91\)90012-8](https://doi.org/10.1016/0003-9993(91)90012-8)  
461
- 462 Kotov, R., Krueger, R. F., Watson, D., Achenbach, T. M., Althoff, R. R., Bagby, R. M., Brown,  
463 T. A., Carpenter, W. T., Caspi, A., Clark, L. A., Eaton, N. R., Forbes, M. K., Forbush, K.,  
464 T., Goldberg, D., Hasin, D., Hyman, S. E., Ivanova, M. Y., Lynam, D. R., Markon, K.,  
465 Miller, J. D., Moffitt, T. E., Morey, L. C., Mullins-Sweatt, S. N., Ormel, J., Patrick, C. J.,  
466 Regier, D. A., Rescorla, L., Ruggero, C. J., Samuel, D. B., Sellbom, M., Simms, L. J.,

- 467 Skodol, A. E., Slade, T., South, S. C., Tackett, J. L., Waldman, I. D., Waszczuk, M. A.,  
468 Widiger, T. A., Wright, A. G. C., & Zimmerman, M. (2017, May). The Hierarchical  
469 Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional  
470 nosologies. *J Abnorm Psychol*, *126*(4), 454-477. <https://doi.org/10.1037/abn0000258>  
471
- 472 Kotov, R., Ruggero, C. J., Krueger, R. F., Watson, D., Yuan, Q., & Zimmerman, M. (2011, Oct).  
473 New dimensions in the quantitative classification of mental illness. *Arch Gen Psychiatry*,  
474 *68*(10), 1003-1011. <https://doi.org/10.1001/archgenpsychiatry.2011.107>  
475
- 476 Ladwig, K. H., Marten-Mittag, B., Erazo, N., & Gundel, H. (2001, Nov-Dec). Identifying  
477 somatization disorder in a population-based health examination survey: psychosocial  
478 burden and gender differences. *Psychosomatics*, *42*(6), 511-518.  
479 <https://doi.org/10.1176/appi.psy.42.6.511>  
480
- 481 Ladwig, K. H., Marten-Mittag, B., Formanek, B., & Dammann, G. (2000, Jun). Gender  
482 differences of symptom reporting and medical health care utilization in the German  
483 population. *Eur J Epidemiol*, *16*(6), 511-518. <https://doi.org/10.1023/a:1007629920752>  
484
- 485 Lautenschlager, G. J., & Mendoza, J. L. (1986, Jun). A Step-down Hierarchical Multiple-  
486 Regression Analysis for Examining Hypotheses About Test Bias in Prediction. *Applied*  
487 *Psychological Measurement*, *10*(2), 133-139. <https://doi.org/10.1177/014662168601000202>  
488  
489

- 490 Main, C. J. (1983). The Modified Somatic Perception Questionnaire (MSPQ). *J Psychosom Res*,  
491 27(6), 503-514. [https://doi.org/10.1016/0022-3999\(83\)90040-5](https://doi.org/10.1016/0022-3999(83)90040-5)  
492
- 493 Marek, R. J., Anderson, J. L., Tarescavage, A. M., Martin-Fernandez, K., Haugh, S., Block, A.  
494 R., Heinberg, L. J., Jimenez, X., & Ben-Porath, Y. S. (2020, Feb). Elucidating  
495 somatization in a dimensional model of psychopathology across medical settings. *J*  
496 *Abnorm Psychol*, 129(2), 162-176. <https://doi.org/10.1037/abn0000475>  
497
- 498 Marek, R. J., & Ben-Porath, Y. S. (2017). Using the Minnesota Multiphasic Personality  
499 Inventory–2–Restructured Form (MMPI-2-RF) in Behavioral Medicine Settings. In M. E.  
500 Maruish (Ed.), *Handbook of Psychological Assessment in Primary Care Settings, Second*  
501 *Edition* (pp. 631-662). Routledge.  
502
- 503 Marek, R. J., Ben-Porath, Y. S., Epker, J. T., Kreymer, J. K., & Block, A. R. (2020, Jan-Feb).  
504 Reliability and Validity of the Minnesota Multiphasic Personality Inventory - 2 -  
505 Restructured Form (MMPI-2-RF) in Spine Surgery and Spinal Cord Stimulator Samples.  
506 *J Pers Assess*, 102(1), 22-35. <https://doi.org/10.1080/00223891.2018.1488719>  
507
- 508 Marek, R. J., Ben-Porath, Y. S., Sellbom, M., McNulty, J. L., & Heinberg, L. J. (2015, May-  
509 Jun). Validity of Minnesota Multiphasic Personality Inventory - 2 - Restructured Form  
510 (MMPI-2-RF) scores as a function of gender, ethnicity, and age of bariatric surgery  
511 candidates. *Surg Obes Relat Dis*, 11(3), 627-634.  
512 <https://doi.org/10.1016/j.soard.2014.10.005>

513

514 Marek, R. J., Block, A. R., & Ben-Porath, Y. S. (2015, Mar). The Minnesota Multiphasic  
515 Personality Inventory-2-Restructured Form (MMPI-2-RF): incremental validity in  
516 predicting early postoperative outcomes in spine surgery candidates. *Psychol Assess*,  
517 27(1), 114-124. <https://doi.org/10.1037/pas0000035>

518

519 Marek, R. J., Block, A. R., & Ben-Porath, Y. S. (2019, Jul). Validation of a Psychological  
520 Screening Algorithm for Predicting Spine Surgery Outcomes. *Assessment*, 26(5), 915-  
521 928. <https://doi.org/10.1177/1073191117719512>

522

523 McBeth, J., Prescott, G., Scotland, G., Lovell, K., Keeley, P., Hannaford, P., McNamee, P.,  
524 Symmons, D. P., Woby, S., & Gkazinou, C. (2012). Cognitive behavior therapy, exercise,  
525 or both for treating chronic widespread pain. *Arch Intern Med*, 172(1), 48-57.  
526 [https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/1108641/loi15076\\_48](https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/1108641/loi15076_48_57.pdf)  
527 [\\_57.pdf](https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/1108641/loi15076_48_57.pdf)

528

529 McCord, D. M., & Drerup, L. C. (2011, Jan). Relative practical utility of the Minnesota  
530 Multiphasic Personality Inventory-2 Restructured Clinical Scales versus the Clinical  
531 Scales in a chronic pain patient sample. *J Clin Exp Neuropsychol*, 33(1), 140-146.  
532 <https://doi.org/10.1080/13803395.2010.495056>

533

534 Pollard, C. A. (1984, Dec). Preliminary validity study of the pain disability index. *Percept Mot*  
535 *Skills*, 59(3), 974. <https://doi.org/10.2466/pms.1984.59.3.974>



536

537 Sellbom, M. (2017, Jul-Aug). Mapping the MMPI-2-RF Specific Problems Scales Onto Extant

538 Psychopathology Structures. *J Pers Assess*, 99(4), 341-350.539 <https://doi.org/10.1080/00223891.2016.1206909>

540

541 Sellbom, M. (2019, May 7). The MMPI-2-Restructured Form (MMPI-2-RF): Assessment of

542 Personality and Psychopathology in the Twenty-First Century. *Annu Rev Clin Psychol*,543 15, 149-177. <https://doi.org/10.1146/annurev-clinpsy-050718-095701>

544

545 Tait, R. C., Chibnall, J. T., &amp; Krause, S. (1990, Feb). The Pain Disability Index: psychometric

546 properties. *Pain*, 40(2), 171-182. [https://doi.org/10.1016/0304-3959\(90\)90068-o](https://doi.org/10.1016/0304-3959(90)90068-o)

547

548 Tarescavage, A. M. (2015). *Predicting treatment outcomes among low back pain patients using*549 *the Minnesota Multiphasic Personality Inventory-2-Restructured Form* Kent State

550 University].

551

552 Tarescavage, A. M., Scheman, J., &amp; Ben-Porath, Y. S. (2015, Jun). Reliability and validity of the

553 Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) in

554 evaluations of chronic low back pain patients. *Psychol Assess*, 27(2), 433-446.555 <https://doi.org/10.1037/pas0000056>

556

557 Tarescavage, A. M., Scheman, J., &amp; Ben-Porath, Y. S. (2018, Mar). Prospective Comparison of

558 the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) and MMPI-2-Restructured

- 559 Form (MMPI-2-RF) in Predicting Treatment Outcomes Among Patients with Chronic  
560 Low Back Pain. *Journal of Clinical Psychology in Medical Settings*, 25(1), 66-79.  
561 <https://doi.org/10.1007/s10880-017-9535-6>  
562
- 563 Tellegen, A., & Ben-Porath, Y. S. (2008/2011). *The Minnesota Multiphasic Personality*  
564 *Inventory-2 Restructured Form (MMPI-2-RF): Technical Manual*. University of  
565 Minnesota Press. [http://www.pearsonassessments.com/HAIWEB/Cultures/en-](http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?Pid=PAg523&Mode=summary)  
566 [us/Productdetail.htm?Pid=PAg523&Mode=summary](http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm?Pid=PAg523&Mode=summary)  
567
- 568 Von Korff, M., Crane, P., Lane, M., Miglioretti, D. L., Simon, G., Saunders, K., Stang, P.,  
569 Brandenburg, N., & Kessler, R. (2005, Feb). Chronic spinal pain and physical-mental  
570 comorbidity in the United States: results from the national comorbidity survey  
571 replication. *Pain*, 113(3), 331-339. <https://doi.org/10.1016/j.pain.2004.11.010>  
572

573 Table 1.  
 574 Additional demographic data of patients in the current sample.  
 575

<b>Demographic Characteristics</b>	<b>Prevalence</b>
Reason for Evaluation	
Spinal Cord Stimulator	43.00%
Medication Management	43.50%
Psychological Services	13.50%
Receiving Disability Benefits	36.08%
Currently Participating in Outpatient Mental Health Treatment	11.73%
History of Participating in Outpatient Mental Health Treatment	50.00%
History of Inpatient Psychiatric Hospitalization	12.24%
Currently Prescribed a Psychotropic Medication	60.91%
History of Having Taken a Psychotropic Medication	66.84%
Currently Taking a Pain Medication	93.88%
Currently Undergoing Physical or Occupational Therapy	1.04%

MMPI-2-RF AND CHRONIC PAIN

28

Degenerative Disc-Spinal Injury	78.71%
Herniated Nucleus Pulposus	57.89%
Disc Bulge/Protrusion	75.33%
Neural Impingement	50.99%
Laminectomy	35.75%
Fusion/Hardware	39.69%

---

577 Table 2.

578 *Sample Means and SDs of MMPI-2-RF Scale Scores by Gender*

	Men (n = 83)		Women (n = 117)		<i>t</i> ( <i>df</i> )	<i>p</i> -value	Cohen's <i>d</i>
	M	SD	M	SD			
<b>MMPI-2-RF Scale Scores</b>							
Somatic Complaints	70	11	74	12	2.58 (198)	.011	.35
Malaise	76	9	77	9	.92 (198)	.358	.11
Gastrointestinal Complaints	61	16	66	18	1.88 (198)	.062	.29
Head Pain Complaints	63	9	67	11	3.05 (191.69)	.003	.39
Neurological Complaints	71	12	73	13	1.27 (198)	.207	.16
Cognitive Complaints	60	13	64	14	2.15 (198)	.033	.30

579 Note: MMPI-2-RF (Minnesota Multiphasic Personality Inventory – 2 – Restructured Form); n(sample size); M(Mean); SD (Standard  
580 Deviation);

581 Table 3.  
 582 *Sample Means and SDs of External Criteria by Gender*

	Men		Women		<i>t</i> ( <i>df</i> )	<i>p</i> -value	Cohen's <i>d</i>
	M	SD	M	SD			
PDI Scale Score	41.97	19.25	44.75	14.61	1.01 (116.90)	.313	.17
MSPQ Scale Score	10.42	6.84	13.93	7.25	3.17 (169)	.002	.50
SCID Somatization Symptom Count	8.28	5.25	9.79	5.51	1.93 (196)	.055	.28

583  
 584 Note: Sample sizes differed between measures. For the PDI scale scores, data were available for 68 men and 102 women. For the MSPQ  
 585 scale scores, data were available for 69 men and 102 women. For SCID Somatization Symptom Count, data were available for 81 men  
 586 and 117 women. PDI (Pain Disability Index); MSPQ (Modified Somatic Perception Questionnaire); SCID (Structured Clinical  
 587 Interview for DSM-IV-TR); n(sample size); M(Mean); SD (Standard Deviation);

588

589 Table 4.

590

591 *Correlations and Partial Correlations Between Minnesota Multiphasic*592 *Personality Inventory-2-Restructured Form Somatic/Cognitive Scale and External*593 *Criteria*

	PDI	Partial Correlation PDI	MSPQ	Partial Correlation MSPQ	SCID-Based Somatization Sx- Total	Partial Correlation SCID-Based Somatization Sx- Total
RC1	.28**	.27**	.62**	.60**	.35**	.33**
MLS	.48**	.48**	.33**	.32**	.20**	.20**
GIC	.10	.09	.45**	.43**	.27**	.25**
HPC	.22**	.21**	.49**	.46**	.28**	.26**
NUC	.30**	.30**	.44**	.43**	.28**	.27**
COG	.26**	.25**	.34**	.32**	.29**	.28**

594 *Note:* Partial correlation coefficients control for gender; PDI = Pain Disability Index;

595 MSPQ = Modified Somatic Perception Questionnaire; SCID = Structured Clinical

596 Interview for DSM-IV-TR; RC1 = Somatic Complaints; MLS = Malaise; GIC =

597 Gastrointestinal Complaints; HPC = Head Pain Complaints; NUC = Neurological

598 Complaints; COG = Cognitive Complaints

599 \*  $p < .05$ . \*\*  $p < .01$ .

600 Table 5  
 601  
 602 Differential Validity Analyses  
 603  
 604

Criteria	MMPI-2- RF Scale	Prediction Model R <sup>2</sup>	Full Model R <sup>2</sup>	Full and Prediction Model $\Delta R^2$	Slope Bias $\Delta R^2$	Intercept Bias $\Delta R^2$
PDI	RC1	.080	.082	.002	-	-
	MLS	.232	.236	.004	-	-
	GIC	.050	.053	.003	-	-
	HPC	.050	.053	.003	-	-
	NUC	.092	.120	.028	-	-
	COG	.067	.071	.004	-	-
MSPQ	RC1	.386	.401	.015	-	-
	MLS	.107	.163	.056**	.012	.044**
	GIC	.237	.256	.019	-	-
	HPC	.237	.256	.019	-	-
	NUC	.198	.235	.037*	.004	.033**
	COG	.118	.158	.040*	.002	.039**
SCID	RC1	.120	.127	.007	-	-
	MLS	.042	.058	.016	-	-
	GIC	.077	.086	.009	-	-
	HPC	.077	.086	.009	-	-
	NUC	.079	.091	.012	-	-
	COG	.085	.103	.018	-	-

605 Note: \*p < .05; \*\*p < .01; R<sup>2</sup>.010 = Small Effect Size, .090 = Medium Effect Size, .250 =  
 606 Large Effect Size  
 607